Prolepsia forecastYes / no
Will Eli Lilly's reported revenue for full-year 2027 be at least 25% higher than its revenue for full-year 2026?
As of 17 November 2026, Prolepsia puts the chance of yes at 15%.
15%chance of yes
How Prolepsia reasons
The report Prolepsia wrote with this forecast.
How forecasts are made · Track record
TL;DR
Probability of Yes: 15.2%. Probability of No: 84.8%. As of November 17, 2026, the analyst consensus points to about 16% revenue growth for Eli Lilly in FY2027, well below the 25% cutoff.
Key evidence
Lilly’s October 29 guidance put FY2026 revenue at $91–92 billion, implying a FY2027 hurdle of $113.75–115.00 billion. The November 16 Tickerix consensus puts the two years at $91.67 billion and $106.49 billion. That leaves FY2027 about $8.10 billion short of the $114.59 billion hurdle implied by the consensus FY2026 figure. The actual test uses reported worldwide consolidated GAAP revenue, not guidance or estimates. (Lilly Q3 results)
Management identified roughly $2 billion of FY2026 milestone and rebate-estimate benefits it does not expect to recur. Those dollars still count in the FY2026 comparison. The quarterly trajectory illustrates the challenge: if Q1 2027 comes in at the $23.55 billion estimate, the remaining quarters need to average $30.35 billion, versus $24.40 billion reported in Q3 2026. The Q1 estimate has only five contributors, so that calculation is a cross-check, not a firm projection. (Q3 earnings call; Q3 Form 10-Q; Tickerix)
Uncertainties
The clearest path to YES is faster-than-expected Mounjaro and Zepbound volume growth despite lower realized prices. A full year of Medicare Bridge access and a stronger Foundayo rollout could help, but more prescriptions do not translate directly into more revenue: some patients switch from other Lilly products or from channels that pay more. Manufacturing is another unknown. Lilly plans to open its Lebanon active-ingredient plant in 2027, but has not disclosed a start month or expected 2027 output. Actual FY2026 revenue, Lilly’s first FY2027 guidance, and paid refills at realized prices are the most useful next checks. (CMS Bridge update; Lilly’s Indiana manufacturing update)
Read the full report
TL;DR
Probability of Yes: 15.2%. Probability of No: 84.8%. The November 16 analyst consensus puts Lilly’s FY2027 revenue $8.10 billion below the level needed for 25% growth. (Tickerix)
Context
As of November 17, 2026, Lilly’s latest FY2026 revenue guidance is $91–92 billion. That puts the provisional FY2027 hurdle at $113.75–115.00 billion, or $114.375 billion at the midpoint. Lilly reported $24.397 billion in Q3 2026, up about 39% year over year. Demand is still growing fast, but FY2027 has to build on a much bigger base. (Q3 results; Q3 Form 10-Q)
The test is worldwide consolidated GAAP revenue in nominal U.S. dollars. Exactly 25% growth counts as YES. The comparison uses the full reported amounts and, when available, the FY2026 comparative column in the FY2027 Form 10-K. Milestones, rebates, currency moves and acquired sales count to the extent they are reflected in reported revenue. The estimates here show the scale of the hurdle; they do not set it.
Evidence
Lilly has cleared 25% growth before, but only during the latest phase of its launch cycle. Annual growth was about 0.8% in FY2022, 19.6% in FY2023, 32.0% in FY2024 and 44.7% in FY2025. Revenue rose from $45.043 billion in FY2024 to $65.179 billion in FY2025. Both of those years beat the midpoint of initial revenue guidance by roughly 10%. That history makes another upside surprise plausible. It does not make a similar beat against a late-2026 consensus the default: FY2026 guidance already moved from $80–83 billion in February to $82–85 billion in April, $85–87 billion in August and $91–92 billion in October. (FY2023 Form 10-K; FY2025 Form 10-K; Q2 results; Q3 results)
The dated analyst estimates give a better starting point than extrapolating those growth rates. The November 16 Tickerix figures are $91.67 billion for FY2026 and $106.49 billion for FY2027, implying about 16.2% growth and a $114.59 billion hurdle. Even the $114.30 billion high estimate for FY2027 falls just short if FY2026 lands at the midpoint of company guidance. It would clear if FY2026 revenue were $91.44 billion or less. The high estimate is not a ceiling, and the two years’ estimates are not paired analyst by analyst. A separate QDD snapshot put FY2027 at about $107.66 billion, still several billion below the hurdle. (Tickerix; QDD Research)
Mounjaro and Zepbound are large enough to close the gap. Together they generated $43.768 billion in the first nine months of 2026, about 65% of Lilly’s revenue. International Mounjaro sales grew 93% year over year in Q3, even as reimbursement in China lowered realized prices. Across Lilly, volume contributed 53 percentage points to Q3 revenue growth, while pricing took away 15 points. Under a central set of assumptions for Foundayo and the rest of the portfolio, the combined tirzepatide franchise needs roughly 35% net sales growth to reach the hurdle. More prescriptions help, but the number that matters is sales after discounts and rebates. (Q3 Form 10-Q; Q3 results)
The Medicare GLP-1 Bridge gives Lilly a full year of wider access in 2027, not an entirely new year of sales. Lilly reported 222,000 Bridge prescriptions in July, 396,000 in August and 527,000 in September. At $245 in manufacturer net revenue per monthly supply, holding September’s rate flat would imply about $1.55 billion in FY2027 channel revenue. If Q4 2026 also held September’s pace, the year-over-year channel increase would be about $0.88 billion before accounting for patients switching from other channels or Lilly products. That is a useful measure of scale, not a separate amount to add to product sales. (Lilly Q3 earnings slides; CMS Bridge update; CMS provider guidance)
Foundayo gives Lilly another way to grow, but the launch has yet to show sales on the scale needed to close the gap. Lilly reported $98 million in Q2, $184 million in Q3 and $281 million through September, as separately rounded. China’s November 12 obesity approval expands the opportunity. The October 15 European committee opinion was not itself a marketing authorization or a reimbursement decision. Novo’s oral Wegovy is already on sale, and a patient who switches from a Lilly injectable to Foundayo does not add the full value of a new prescription to Lilly’s revenue. Retatrutide is another source of upside, but a Q1 2027 filing target is not a launch date. (Q2 results; Q3 Form 10-Q; China approval; European committee opinion; Q3 earnings call)
What's non-obvious
The headline growth rate understates how tough the comparison is. Management said roughly $2 billion of FY2026 milestone and rebate-estimate benefits are not expected to recur. They still count toward FY2026 revenue. At the $91.67 billion consensus base, Lilly needs about $22.92 billion in reported growth, or about $24.92 billion in additional revenue over the base excluding those benefits if nothing replaces them. The second number explains the operating challenge; it does not change the resolution rule. (Q3 earnings call; Tickerix)
The quarterly math also shows how much acceleration is needed. Lilly reported $19.799 billion, $22.974 billion and $24.397 billion in the first three quarters of 2026. If Q1 2027 matches the $23.55 billion estimate, the final three quarters must average $30.35 billion to clear the consensus-based hurdle. That Q1 estimate has only five contributors, so it is a cross-check. Capacity announcements do not settle whether Lilly can deliver that ramp. The Lebanon active-ingredient plant is slated to open in 2027, but there is no disclosed start month or 2027 output. The November 12 Lehigh Valley groundbreaking targets operation by 2031, too late to help in 2027. (Q3 Form 10-Q; Tickerix; Indiana manufacturing update; Lehigh Valley announcement)
Uncertainties
The strongest upside case is that international Mounjaro and U.S. Zepbound volumes rise faster than expected without a matching fall in realized prices. The biggest gaps are post-September Bridge fills by product, how many patients keep refilling, and how much of the growth comes from patients who would otherwise have bought another Lilly drug or paid through a different channel. Foundayo’s foreign approvals also leave open when patients gain reimbursed access and at what price. The first useful update is Lilly’s actual FY2026 revenue alongside its initial FY2027 guidance. After that, paid refills and net sales by product and geography will say more about the odds of clearing the hurdle than another approval or prescription headline.
Forecast history
| Date | Forecast |
|---|---|
| 15% chance of yes |
Sources Prolepsia read
- LLY Stock Price — Eli Lilly and Company Analysis | Tickerixtickerix.com
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio | Eli Lilly and Companyinvestor.lilly.com
- lly-20260930www.sec.gov
- Eli Lilly and Company (LLY) Stock Report: Quant Rating A, Valuation & Estimates | QDD Researchwww.qddresearch.com
- Status Update on the BRIDGE Demo and BALANCE Model in Part D for CY2027www.cms.gov
- 中国首个且唯一口服减重GLP-1类药物穆优达®(奥氟格列隆)获批-美通社PR-Newswirewww.prnasia.com
- European committee opinionwww.ema.europa.eu
- Indiana manufacturing updatewww.prnewswire.com
- Trump Touts Lilly’s “$3.5 Billion” Obesity Drug Plant, Its 10th New U.S. Site Since 2020 | TIKR.comwww.tikr.com
- Eli Lilly and Company (LLY) Analyst Ratings, Estimates & Forecasts - Yahoo Financefinance.yahoo.com
The question
This question asks whether Eli Lilly and Company's total consolidated revenue for fiscal year 2027 (January 1 through December 31, 2027) will be at least 25% greater than its total consolidated revenue for fiscal year 2026 (January 1 through December 31, 2026). The forecast is made as of November 17, 2026, and will be resolved after Eli Lilly publishes its full-year 2027 financial results, expected in early 2028. Eli Lilly (NYSE: LLY) is a global pharmaceutical company experiencing substantial revenue growth, particularly from its diabetes and obesity treatments Mounjaro and Zepbound. According to its 2025 Form 10-K, Eli Lilly reported consolidated revenue of approximately $65.18 billion for 2025, compared with $45.04 billion in 2024, representing growth of approximately 44.7%. On October 29, 2026, Eli Lilly reported third-quarter 2026 worldwide revenue of approximately $24.4 billion, an increase of 39% year over year. The company also raised its full-year 2026 revenue guidance to $91.0 billion–$92.0 billion. Based on the midpoint of that guidance ($91.5 billion), achieving 25% revenue growth in 2027 would require approximately $114.38 billion in full-year 2027 revenue. This illustrative threshold will be recalculated using actual reported 2026 revenue. The question concerns reported worldwide revenue under U.S. Generally Accepted Accounting Principles (GAAP), rather than adjusted revenue, organic revenue growth, earnings, profits, or individual product sales. Background sources: Eli Lilly's 2025 Form 10-K (https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm) and its October 29, 2026 third-quarter earnings announcement (https://investor.lilly.com/news-releases/news-release-details/lilly-reports-third-quarter-2026-financial-results-raises-full).
How it resolves
The question resolves YES if Eli Lilly and Company's total consolidated GAAP revenue for fiscal year 2027 is greater than or equal to 1.25 times its total consolidated GAAP revenue for fiscal year 2026. It resolves NO if fiscal year 2027 revenue is less than 1.25 times fiscal year 2026 revenue. The calculation is: Revenue Growth (%) = [(FY2027 Revenue / FY2026 Revenue) − 1] × 100. The primary resolution source will be Eli Lilly's fiscal year 2027 Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (SEC), using the consolidated statements of operations and the line item labeled 'Revenue' or its directly equivalent successor. The 2026 comparison figure will be taken from the comparative 2026 column in the same FY2027 Form 10-K, ensuring that both years are measured using consistent accounting policies and any applicable retrospective adjustments. If the FY2027 Form 10-K does not provide a comparable 2026 figure, the FY2026 Form 10-K will be used for that year. Revenue will be measured in U.S. dollars, using the full reported amounts in the financial statements, with no adjustments for inflation, exchange-rate movements, acquisitions, divestitures, or changes in product mix beyond those reflected in GAAP reporting. The comparison will use the precision available in the financial statements, without rounding the calculated growth percentage before determining whether the 25% threshold has been met. If the FY2027 Form 10-K is unavailable by June 30, 2028, Eli Lilly's official full-year 2027 earnings release or other SEC-filed financial statements may be used, provided they disclose comparable GAAP revenue figures for both years. If reliable and comparable annual revenue figures cannot be established by December 31, 2028, the question will be annulled rather than resolved YES or NO.
Fine print
The revenue comparison covers the entire consolidated Eli Lilly group worldwide, including all consolidated subsidiaries and business segments, rather than only U.S. operations or specific pharmaceutical products. Revenue from acquisitions, newly introduced drugs, licensing arrangements, and other activities will count to the extent recognized as GAAP revenue in the relevant fiscal year. Revenue growth will be measured using nominal U.S. dollars and will not be adjusted for currency fluctuations or inflation. If Eli Lilly restates its 2026 revenue in its FY2027 Form 10-K, the restated comparative figure will be used. Subsequent restatements published after the question has been resolved will not change the outcome. If Eli Lilly changes its fiscal year-end, the comparison will use the company's reported annual periods corresponding most closely to calendar years 2026 and 2027, provided they remain meaningfully comparable; otherwise, the question will be annulled. If Eli Lilly merges with another company, is acquired, or undergoes a major corporate restructuring before the end of 2027, the question will remain resolvable if comparable consolidated revenue figures attributable to the continuing Eli Lilly reporting entity are available for both years. Otherwise, it will be annulled. The resolution is based on officially reported revenue, not analyst estimates, management projections, or preliminary guidance. The threshold is inclusive: revenue growth of exactly 25.000% resolves YES.
More public forecasts
What will be the highest success rate on ExploitGym's full 869-task suite with exploit mitigations switched on, reported by 30 June 2027?
56.2median
Prolepsia forecast
What will be the highest success rate on ExploitGym's full 869-task suite reported for an open-weight model by 30 June 2027?
49.5median
Prolepsia forecast
What will be the highest success rate on ExploitGym's full 869-task suite reported for any AI model or agent system by 30 June 2027?
70.3median
Prolepsia forecast
Will Nvidia's data center revenue for its fiscal year ending January 2028 exceed $300 billion?
95%chance of yes
Prolepsia forecast
Will more than 30% of EU enterprises use AI in 2027, as reported by Eurostat?
98%chance of yes
Prolepsia forecast
Will US retail sales at clothing and clothing accessories stores grow faster in 2027 than total US retail sales, as reported by the Census Bureau's monthly retail trade survey?
66%chance of yes
Prolepsia forecast